TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech company completed its $600 million acquisition of Ambry Genetics.

TD Cowen analyst Dan Brennan reinstated coverage of Tempus AI (TEM) with a Buy rating and price target of $74, up from $58, following the ...

Up about 12%, Tempus AI (NASDAQ:TEM) has been explosive. Helping, its volume just spiked to 18.6 million shares, as compared ...

Tempus AI (TEM) is soaring 13% today after investment bank TD Cowen reinstated coverage of the shares with a Buy rating. TEM ...

TD Cowen reaffirmed their buy rating on shares of Tempus AI (NASDAQ:TEM – Free Report) in a research note published on Wednesday, Marketbeat Ratings reports. TD Cowen currently has a $74.00 price ...

Multiple executives at Tempus AI Inc. executed significant share sales totaling $20.3 million between Feb. 4-7, according to ...

TD Cowen reinitiated coverage on Tempus AI Inc (NASDAQ:TEM) with a Buy rating, increasing the price target to $74 from a previous target. The stock, currently trading at $61.85, has shown remarkable ...

The stock market extended its winning streak on Wednesday, closing firmer as investors seemed to have already priced in the ...

James William Rogers (NYSE:ROG), the Chief Financial Officer of Tempus AI , Inc. (NASDAQ:TEM), recently sold 8,712 shares of the company’s Class A common stock. The shares were sold at a weighted ...

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free ...